Complications of COVID-19 and possible role of angiotensin converting enzyme inhibitors and anti-platelet medications in lowering the risk of COVID -19 infection
Department of Pharmacology, Aditya College of Pharmacy, Surampalem, Kakinada District, Andhra Pradesh, India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2023, 25(02), 198–203.
Article DOI: 10.30574/gscbps.2023.25.2.0474
Publication history:
Received on 29 September 2023; revised on 08 November 2023; accepted on 11 November 2023
Abstract:
COVID-19, the worldwide pandemic which effected the entire health care system, particularly showed its ill effects on patients with many comorbidities. Among the COVID-19 patients admitted in hospital, are with cardiovascular diseases and hypertension where associated with increased risk of mortality. Angiotensin converting enzyme inhibitors (ACEI) and Angiotensin receptor-II blockers (ARB) were used in the management of hypertension and these medications revealed their beneficiary actions in the conditions of COVID -19 with Hypertension. On the other hand, COVID -19 also lead to thromboembolic complications which also required Intensive Care Unit admission within patients representing a unique condition termed as Covid Associated Coagulopathy (CAC). The impact of dual anti-platelet therapy reduced the risk of mechanical ventilation, ICU admission and mortality rate among individuals effected by Covid.
Keywords:
Cardiovascular diseases; Thromboembolic diseases; Covid Associated Coagulopathy; Angiotensin converting enzyme inhibitors; Angiotensin receptor-II blockers; Anti-platelet therapy
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
